(Q35198551)

7 August 2017

1 reference

title

The anabolic effects of parathyroid hormone therapy (English)

1 reference

7 August 2017

2

John P Bilezikian

1 reference

7 August 2017

1

Mishaela R Rubin

1 reference

7 August 2017

1 May 2003

1 reference

Clinics in geriatric medicine

7 August 2017

1 reference

7 August 2017

19

1 reference

7 August 2017

2

1 reference

7 August 2017

415-432

1 reference

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Skeletal disease in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Dissociation of second messenger activation by parathyroid hormone fragments in osteosarcoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Anabolic effects of parathyroid hormone on bone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: exceptions that provide the rules

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Osteocytes and bone lining cells: which are the best candidates for mechano-sensors in cancellous bone?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Synergistic effect of PTH on the mechanical responses of human alveolar osteocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34).

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Human parathyroid peptide treatment of vertebral osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Primary hyperparathyroidism: changes in trabecular bone remodeling following surgical treatment--evaluated by histomorphometric methods

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Survival after the diagnosis of hyperparathyroidism: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900074-5

7 January 2021

10.1016/S0749-0690(02)00074-5

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12916294